The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Zorevunersen was generally well tolerated across the studies. To date, more than 600 doses of zorevunersen have been administered to patients, some of whom have been on treatment for more than ...

Zorevunersen was generally well-tolerated across these studies. "Effects on behavior and cognition are a key secondary endpoint in our Phase 3 EMPEROR study," said Barry Ticho, M.D., Ph.D., Chief ...

About Zorevunersen Zorevunersen is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials.

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

Zorevunersen is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both ...